Clearmind Medicine Expands Alcohol Use Disorder Trial
Ticker: CMND · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1892500
| Field | Detail |
|---|---|
| Company | Clearmind Medicine INC. (CMND) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, expansion, pharmaceutical
TL;DR
Clearmind adds another site to its alcohol disorder trial, aiming to speed things up.
AI Summary
Clearmind Medicine Inc. announced on November 20, 2025, that it has activated a fifth global medical site for its FDA-approved clinical trial for alcohol use disorder. This expansion aims to accelerate the trial's progress by increasing patient enrollment capacity.
Why It Matters
The activation of a new trial site could speed up the development of potential treatments for alcohol use disorder, a significant public health issue.
Risk Assessment
Risk Level: medium — The company is in clinical trials, which carry inherent risks of failure and regulatory hurdles.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- November 20, 2025 (date) — Press release date
- FDA (company) — Regulatory body overseeing the trial
FAQ
What is the specific title of the press release attached to this 6-K filing?
The press release is titled 'Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site'.
What is the Commission file number for Clearmind Medicine Inc.?
The Commission file number is 001-41557.
What is Clearmind Medicine Inc.'s fiscal year end?
Clearmind Medicine Inc.'s fiscal year end is October 31.
Which form does Clearmind Medicine Inc. indicate it files annual reports under?
Clearmind Medicine Inc. indicates it files annual reports under Form 20-F.
What is the business address of Clearmind Medicine Inc.?
The business address is 101-1220 West 6th Avenue, Vancouver, British Columbia, V6H1A5.
Filing Stats: 277 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2025-11-20 08:08:09
Filing Documents
- ea0266569-6k_clearmind.htm (6-K) — 11KB
- ea026656901ex99-1_clearmind.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-25-112853.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: November 20, 2025 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3